IT firms see shift to shorter deal cycles

Deal cycles in India’s IT services sector are becoming shorter, even for large contracts – a trend analysts expect to continue in the coming quarters. This shift reflects rapid technological advancements and evolving client priorities, pushing companies to prioritise flexibility and agility over long-term commitments.

HCLTech CEO and managing director C Vijayakumar noted during a post-earnings press conference: “We’re seeing the average duration of signed deals getting shorter, which naturally leads to a moderated total contract value (TCV). However, the more important metric here is annual contract value (ACV), which remains strong”.

Also ReadBlinkit’s losses widens to Rs 103 crore amid aggressive expansion plans

HCLTech reported a slight sequential decline in deal wins, with its TCV at $2.1 billion for the December quarter compared to $2.2 billion in the previous quarter.

Similarly, Wipro’s CFO Aparna Iyer observed a decline in large deals but highlighted increased momentum in small and medium-sized contracts. “This is just one quarter, so we will need two or three more quarters to determine the trend,” she said. Wipro secured $1 billion in large deals during the quarter, with total deal wins amounting to $3.51 billion.

Clients are increasingly favouring shorter-term contracts to adapt to rapidly changing tech landscapes. Pareekh Jain, CEO of Pareekh Consulting, explained: “Deals are shifting from cost takeout projects to business transformation and generative AI initiatives. Clients want faster, more flexible solutions, which is why deal durations are reducing.”

Debashis Chatterjee, CEO of LTIMindtree, echoed this sentiment: “Deal cycles are definitely shorter than they were a year ago because clients are closing deals faster.”

Analysts suggest that while shorter deal tenures may reduce TCV in some cases, the overall increase in deal volumes and quicker decision-making could prove beneficial for the industry.

Tata Consultancy Services (TCS) observed a reduction in deal cycles by a few weeks, signaling faster client decision-making. K Krithivasan, CEO and managing director of TCS, said: “We reviewed deals exceeding $20 million and found a reduction in deal cycles, indicating improved client decision-making”. TCS’s TCV grew 18.6% sequentially to $10.2 billion, encompassing both new and existing contracts.

Also ReadVodafone Idea says ‘no communication yet’ on media reports of govt weighing Rs 1 lakh crore AGR dues waiver

While Infosys did not report significant changes in deal cycles,

 » Read More

Related Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies has maintained a Buy on JB Pharma with a revised target price of Rs 2,310. The stock currently trades at Rs 1,714/share implying an 34% upside. This new target price is just a shade lower than the previous target price of Rs 2,340. According to Jefferies, an international brokerage house, the growth drivers are

Two banking stocks to watch ahead of the RBI Policy

By Kiran Jani Bank Nifty reached its all-time high of 54,467 in September 2024. Following this peak, the index experienced a correction, dipping to 47,844 in January 2025—a decline of 7.29%. Despite this pullback, Kotak Bank and ICICI Bank showed relative resilience, delivering returns of 1.61% and -4.20%, respectively, during the same period. Source: Investing.com

New Tax Regime: These deductions, exemptions still available for you

The Indian government introduced a new tax regime in 2020, offering lower tax rates while removing several exemptions and deductions available under the old system. Initially optional, this regime became the default in 2023, requiring taxpayers to opt out if they wished to continue under the old structure. Despite the removal of many benefits, certain

Range bound session: Nifty ends above 23,600, Sensex holds 78,000 led by Adani Ports, Infosys

The stock markets faced a downturn on Thursday, with major indices closing in the red. The BSE Sensex dropped by 213.12 points or 0.27%, ending the day at 78,058.16, while the NSE Nifty 50 saw a decline of 70.15 points, down by 0.3%, and closed at 23,626.15. The Nifty Bank index also ended the day

IT stocks stable as Cognizant raises annual and quarterly revenue guidance

Shares of Indian IT companies are in the spotlight today after the Nasdaq-listed IT services major Cognizant Technology Solutions, reported its Q4 results that exceeded Wall Street expectations. The Nifty IT Index as well as individual tech counters like Infosys, Wipro, Tech Mahindra and HCL Tech are all in the green even as the markets